无锡阿科力科技股份有限公司 2025 年第三次临时股东会 会议材料 无锡阿科力科技股份有限公司 2025 年第三次临时股东会 会议材料 二零二五年十一月 无锡阿科力科技股份有限公司 2025 年第三次临时股东会 会议材料 无锡阿科力科技股份有限公司 2025 年第三次临时股东会会议须知 根据中国证券监督管理委员会《上市公司股东会规则》和《公司章程》的 有关规定，为确保无锡阿科力科技股份有限公司（以下简称"公司"）股东会 顺利召开，特制定会议须知如下，望出席股东会的全体人员遵守执行： 一、股东参加股东会，应当认真履行其法定义务，不得侵犯其他股东权益； 二、股东会期间，全体出席人员应以维护股东的合法利益、以确保大会正 常秩序和议事效率为原则，认真履行法定职责； 三、出席会议的股东依法享有发言权、咨询权、表决权等各项权利，但需 由公司统一安排发言和解答； 四、任何人不得扰乱会议的正常秩序和会议程序；会议期间请关闭手机或 将其调至振动状态。 无锡阿科力科技股份有限公司 2025 年第三次临时股东会 会议材料 无锡阿科力科技股份有限公司 2025 年第三次临时股东会 议 程 安 排 一、现场会议召开的日期、时间和地点： ...

证券代码：603722 证券简称：阿科力 公告编号：2025-088 无锡阿科力科技股份有限公司 关于使用闲置自有资金委托理财的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 重要内容提示： ●委托理财受托方：中国银行股份有限公司无锡东亭支行 ●委托理财金额：人民币 2,450.00 万元 ●委托理财产品名称：人民币结构性存款(CSDVY202513483) ●委托理财期限：38 天 ●履行的审议程序：无锡阿科力科技股份有限公司第四届董事会第十四次会 议、第四届监事会第十四次会议、2024 年第二次临时股东大会审议通过了《关 于使用闲置自有资金进行委托理财的议案》，公司对最高额度不超过 20,000 万 元的闲置自有资金进行委托理财，在确保不影响公司日常运营的情况下在股东大 会审议通过之日起 12 个月内滚动使用，并授权公司总经理在上述额度内组织实 施。具体内容详见公司于 2024 年 10 月 26 日在《上海证券报》、《证券时报》、 《金融时报》及上海证券交易所网站披露的《无锡阿科力科技股 ...

Core Points - The stock price of Acoly rose by 2.14% on October 31, reaching 40.07 CNY per share, with a total market capitalization of 3.916 billion CNY [1] - Acoly's main business includes the research, production, and sales of chemical new materials such as polyether amines and optical-grade polymer materials [1][2] - For the first nine months of 2025, Acoly reported a revenue of 337 million CNY, a year-on-year decrease of 7.46%, and a net profit attributable to shareholders of -16.39 million CNY, a year-on-year decrease of 141.59% [2] Financial Performance - Acoly has seen a stock price decline of 4.37% year-to-date, with a 0.52% drop over the last five trading days and a 7.86% decline over the last 20 days [1] - The company has a shareholder count of 8,766 as of September 30, 2025, an increase of 46.74% from the previous period, while the average number of circulating shares per person decreased by 31.85% [2] - Cumulatively, Acoly has distributed 198 million CNY in dividends since its A-share listing, with 53.54 million CNY distributed over the last three years [3] Industry Context - Acoly operates within the basic chemical industry, specifically in the chemical products sector, and is involved in concepts such as optical materials, specialized new materials, and small-cap stocks [2]

关于参加无锡首届上市公司投资者集体接待日活动暨 召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 10 月 30 日(星期四) 至 11 月 3 日(星期一)16:00 前通过公 司邮箱 zq@chinaacryl.com 进行提问。说明会上将对投资者普遍关注的问题进行 回答。 证券代码：603722 证券简称：阿科力 公告编号：2025-087 无锡阿科力科技股份有限公司 无锡阿科力科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 25 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 4 日下午 15:30-17:00 参加无锡首届上市公司投资者集体接待日活动暨召开 2025 年第三季 度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company experienced a decline in profit margins due to increased competition and the need for time to ramp up new product volumes, leading to a downward revision of profit forecasts for 2025-2027 [4][5] - The company achieved a revenue of 337 million yuan in the first three quarters of 2025, a year-on-year decrease of 7.46%, with a net profit attributable to the parent company of -16.39 million yuan, indicating an expanded loss [5] - The company is optimistic about the future of its COC (Cyclic Olefin Copolymer) production, which has entered the formal production phase and is expected to be a significant growth driver [5] Financial Summary - Revenue for Q3 2025 was 123 million yuan, a year-on-year increase of 0.79%, while the net profit attributable to the parent company was -11.08 million yuan, reflecting an expanded loss [5] - The company’s sales volume for fatty amines and optical materials in the first three quarters of 2025 were 14,881 tons and 4,151 tons, respectively, with year-on-year changes of +3.27% and -16.83% [5] - The average price for fatty amines decreased by 10.23% to 13,324 yuan/ton, while the average price for optical materials increased by 10.75% to 33,303 yuan/ton [5] - The company’s projected net profits for 2025, 2026, and 2027 are 5 million yuan, 44 million yuan, and 139 million yuan, respectively, with corresponding EPS of 0.05, 0.45, and 1.42 yuan per share [4][7] Production and Contracts - The company signed a sales contract for COC with a transaction amount of 2.6 million yuan, marking a milestone in its entry into the pharmaceutical packaging sector [5] - The COC production line has completed trial production and is now in formal production, with initial products being tested by downstream clients in various fields [5]

Group 1 - The company announced its third quarter financial report for 2025, ensuring the accuracy and completeness of the information provided [8][10][39] - The company plans to apply for a bank credit limit of up to 200 million RMB for its subsidiary to support daily operations and business development [10][11] - The company will use idle funds for entrusted wealth management, with a maximum amount of 200 million RMB, aiming to improve fund efficiency and returns [13][14][15] Group 2 - The company held its sixth board meeting on October 24, 2025, where several key resolutions were passed, including the approval of the third quarter report and the application for bank credit [39][40][41] - The company will convene its third extraordinary shareholders' meeting on November 10, 2025, to discuss various proposals [20][21][22] - The company plans to provide a loan of up to 50 million RMB to its wholly-owned subsidiary to support its development and operational needs [54][55][56]

Group 1 - Acolyte (SH 603722) announced the convening of its fifth board meeting on October 24, 2025, to review the proposal for the third quarter report of 2025 [1] - For the year 2024, Acolyte's revenue composition is 99.84% from chemical products and 0.16% from other businesses [1] - As of the report, Acolyte's market capitalization stands at 3.9 billion yuan [1] Group 2 - The Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year [1] - The secondary market for biomedicine is experiencing a surge, while the primary market is facing challenges in fundraising [1]

Core Viewpoint - Akole (603722.SH) reported a decline in revenue and incurred losses in the first three quarters of 2025, indicating financial challenges for the company [2] Financial Performance - The company achieved a revenue of 337 million yuan in the first three quarters, representing a year-on-year decrease of 7.46% [2] - The net profit attributable to shareholders was a loss of 16.39 million yuan [2] - The non-recurring net profit also showed a loss of 19.35 million yuan [2] - Basic earnings per share were reported at -0.17 yuan [2]

Core Insights - Akole (603722.SH) reported a revenue of 337 million yuan for the first three quarters of 2025, representing a year-on-year decline of 7.46% [1] - The company recorded a net loss attributable to shareholders of 16.39 million yuan [1] - The non-recurring net profit also showed a loss of 19.35 million yuan, with basic earnings per share at -0.17 yuan [1]

无锡阿科力科技股份有限公司 章 程 二零二五年十月 1 第一章 总则 第一条 为维护无锡阿科力科技股份有限公司（以下简称公司）、股东、职工 和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》 （以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）和其 他有关规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司以有限公司整体变更的方式发起设立；在江苏省无锡市工商行政管理局 注册登记，取得营业执照，统一社会信用代码为 9132020071491965XM。 第三条 公司于 2017 年 9 月 22 日经中国证券监督管理委员会核准，首次向 社会公众发行人民币普通股 2,170 万股，于 2017 年 10 月 25 日在上海证券交易 所上市。 第四条 公司注册名称： 中文全称：无锡阿科力科技股份有限公司 英文全称：WUXI ACRYL TECHNOLOGY CO.,LTD 第五条 公司住所：无锡市锡山区东港镇新材料产业园 邮政编码：214196 第六条 公司注册资本为人民币 9,772.0121 万元。 第七条 公司为永久存续的股份有限公司。 ...